Peter Barrett, PhD, is a partner in the life sciences group at Atlas Venture and focuses on investments in therapeutics and medical technologies that significantly change the medical management of patients. At Atlas, Dr. Barrett has been involved in the creation of several novel therapeutic and drug discovery platform companies, leveraging his background in corporate business development to provide strategic and negotiating guidance to his portfolio; he was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals (NASDAQ: SCLN).  He is currently chairman of Harbour Antibodies, Synlogic, and Zafgen (NASDAQ: ZFGN), and also serves on the boards of Mnemosyne Pharmaceuticals, InfaCare, JenaValve, and Vitae Pharmaceuticals.  Dr. Barrett was previously on the boards of past Atlas companies SciClone Pharmaceuticals, Sirion Therapeutics (acquired by Alcon and Bausch & Lomb), and Archemix (acquired by Baxter).

Prior to joining Atlas in 2002, Dr. Barrett was co-founder, executive vice president, and chief business officer of Celera Genomics.  Within two years of its founding, Celera announced the first successful sequencing of the human genome.  Dr. Barrett helped launch Celera as a publicly traded entity in 1999.  He led Celera’s strategic alliances and acquisitions, and participated in raising nearly $1 billion in capital for the company. Prior to Celera, Dr. Barrett held senior management positions at PerkinElmer, most recently serving as vice president, corporate planning and business development.

Dr. Barrett is currently vice chairman of the advisory council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as adjunct professor at the Barnett Institute.  He also serves as president of the Autism Consortium, a non-profit institution, is a member of the research council at Boston Children’s Hospital, and serves on the board of PerkinElmer.

Dr. Barrett received a BS in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell), and a PhD in analytical chemistry from Northeastern University.  He also completed Harvard Business School’s Management Development Program.

Jason Rhodes joined Atlas Venture in 2014 as a partner in the life sciences group. Prior to joining Atlas, Jason was President and Chief Financial Officer of Epizyme (NASDAQ: EPZM) from 2010 to 2014, and was instrumental in building the business, including its successful IPO in 2013, follow on financing in 2014 and more than $180 million in funding through partnerships with Celgene, GSK, and Eisai. Prior to Epizyme, Jason was Vice President of Business Development at Alnylam (NASDAQ: ALNY), where he brought in more than $200 million in funding through partnerships with Takeda, GSK, Isis, Cubist, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics (NASDAQ: RGLS). Before joining Epizyme, Jason was a founder and partner with Fidelity Biosciences where he led investments in therapeutics companies, including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Tetraphase (NASDAQ: TTPH). While at Fidelity, he was also acting Chief Business Officer of FORUM Pharmaceuticals. Earlier in his career, Jason was a strategy consultant for biopharma and high tech companies. Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
Ansbert Gadicke, MD, co-founded MPM in 1997 with his partner Luke Evnin. Over many years the MPM team has been the inspiration and driving force behind building leading biopharmaceutical companies such as Biomarin, CoStim Pharmaceuticals, Epizyme, Pacira, and Pharmasset; companies that ultimately resulted in helping thousands of patients live longer and with vastly improved lives. Dr. Gadicke was the lead investor and has served on the boards of several of MPM’s investments, including BioMarin, Idenix, and Pharmasset.

Prior to the launching of MPM’s venture investing activities in 1997, Dr. Gadicke led MPM’s Advisory and Investment Banking business from 1992 to 1996, and from 1989 to 1992 he was at The Boston Consulting Group in its Boston office in the Health Care Group. Dr. Gadicke received an MD from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University, and published in leading scientific journals such as Nature and Cell. At the German Cancer Research Center, Dr. Gadicke cloned the first cDNAs of HPV16 and 18 while under the leadership of Professor Harald zur Hausen, who received the Nobel Prize in Physiology or Medicine in 2008.

Dr. Gadicke’s commitment to drug discovery and curing disease inspires his work and that of his team in building leading biotechnology companies at MPM, as well as his commitments outside of MPM. He is a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of Massachusetts General Hospital.

Hakan Goker, PhD, is a senior director at MS Ventures, the corporate venture capital fund of Merck Serono. Hakan joined MS Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of  multiple biotechnology companies globally including Forendo (FI), Orphazyme (DK), F Star (NL), Bicycle Therapeutics (UK),  Nimbus Discovery (US), and Nitec, now Horizon Pharma (CH/US).

Hakan received his PhD in cancer biology from the Institute of Cancer Research/University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours from University College London. Hakan is a board member of Forendo Pharma, Synaffix, Asceneuron, Raze Therapeutics, Tocopherx, and Progyny Inc.